Gujarat Themis Biosyn Ltd
Incorporated in 1981, Gujarat Themis Biosyn
Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]
- Market Cap ₹ 5,602 Cr.
- Current Price ₹ 430
- High / Low ₹ 479 / 225
- Stock P/E 115
- Book Value ₹
- Dividend Yield 0.16 %
- ROCE %
- ROE %
- Face Value ₹ 1.00
Pros
Cons
- Promoter holding has decreased over last quarter: -11.5%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 166 | |
| 90 | |
| Operating Profit | 76 |
| OPM % | 46% |
| 2 | |
| Interest | 3 |
| Depreciation | 13 |
| Profit before tax | 62 |
| Tax % | 25% |
| 47 | |
| EPS in Rs | 4.28 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 51% |
| 5 Years: | 46% |
| 3 Years: | 53% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Total Employee Count Number ・Standalone data |
|
|||||||
| Installed Production Capacity - Rifamycin S and O KG/year ・Standalone data |
||||||||
| Customer Share - Lupin Limited % ・Standalone data |
||||||||
| Customer Share - Optrix Laboratories % ・Standalone data |
||||||||
| Sales Realization per Kg Rs/Kg ・Standalone data |
||||||||
| Sales Volume - Rifamycin S and O KG ・Standalone data |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.09.2026
- Board approved private placement NCD issuance up to INR 585 crore on 10 September 2026.
-
Addendum To The Notice Of 45Th Annual General Meeting ('AGM')
- Addendum to 45th AGM notice for 30 Sept 2026 includes amendment to Articles of Association.
-
Board Meeting Intimation for Raising Funds Through Issue Of Non-Convertible Debentures By Way Of Private Placement.
- Board meeting on 10 September 2026 to approve NCD issue via private placement; trading window closed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Please refer to newspaper publication of 45th AGM notice .
- Reg. 34 (1) Annual Report.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Aug 2026Transcript PPT REC
-
Jun 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Apr 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT REC
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Jun 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptPPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptAI SummaryPPT
Business Overview[1][2]
Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.